Pfizer Inc - PFE StarRatingValueLabel_5Karen Andersen, CFA - Strategist - Morningstar Inc.

Last Price
22.15
Day Change
0.11|0.48%

As of 17/04/2025
16:01:06 EDT | USD  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
22.10 - 22.2522.10 - 22.5551,508,44750,449,484-
Last Close52 Week RangeP/EYield %ISIN
22.0420.92 - 31.5415.637.67US7170811035
Karen Andersen, CFA - Strategist - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Financials
202220232024
more...
Income Statement
Revenue100,330.0058,496.0063,627.00
Operating Income37,272.003,359.0014,938.00
Net Income31,372.002,119.008,031.00
Basic EPS5.590.381.42
Avg. Diluted Shares Outstanding5,7335,6435,700
Balance Sheet
Current Assets51,259.0043,333.0050,358.00
Non Current Assets145,944.00183,168.00163,038.00
Total Assets197,205.00226,501.00213,396.00
Current Liabilities42,138.0047,794.0042,995.00
Total Liabilities---
Total Equity95,661.0089,014.0088,203.00
Cash Flow
Operating Cash Flow29,267.008,700.0012,744.00
Capital Expenditure-3,236.00-3,907.00-2,909.00
Free Cash Flow26,031.004,793.009,835.00

In millions, except "Basic EPS". Currency is USD.

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Value

Fiscal Year Ends

December

Employees

81,000
Key Stats
more...
Price/Earning TTM15.52
Price/Book1.42
Price/Sales TTM1.97
Rev Growth (3 year avg)-7.84
EPS Growth (3 year avg)-
Operating Margin % TTM23.48
Net Margin % TTM12.62
ROE TTM9.06
Debt/Equity0.64
Dividends
PreviousLatest
Declared Date09/10/2412/12/24
Ex-Div08/11/2424/01/25
Paid02/12/2407/03/25
Amnt0.420.43
Karen Andersen, CFA - Strategist - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures